Cardiology

Test your knowledge of Canada’s harmonized prevention and treatment guideline.

In rheumatoid arthritis patients with a history of cardiovascular disease, the risk of major adverse cardiovascular events is higher with tofacitinib than with tumor necrosis factor inhibitors.

The guideline is an update to a 2018 iteration and adds 48 fresh recommendations.

Having previously updated the risks specified on the product monograph for one type of Janus Kinase inhibitor, Health Canada now says it can't rule out similar risks for other types.

Study examines whether ARB therapy is associated with a decreased incidence of new onset epilepsy in patients with hypertension.

Study adds to the debate about use of vasopressors for these patients.

People who are taking common cardiovascular drugs and given Paxlovid (nirmatrelvir/ritonavir) are at risk of drug-drug interactions, according to a review in the Journal of the American College of Cardiology.

Single-dose Evusheld is now indicated for treating mild/moderate COVID-19 and Actemra IV is now approved for treating COVID-19 in hospitalized adults.